MorphoSys AG Company Update September 2016

MorphoSys AG presents a company update highlighting its diverse partnership network, proprietary antibody discovery platforms (HuCAL, Ylanthia), and robust R&D pipeline. The biotech company focuses on developing differentiated therapies for cancer and inflammation with 27 antibodies in clinical development and up to 39 expected clinical readouts in 2016/2017.